Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Anthracyclines

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    129 result(s) found for: Anthracyclines. Displaying page 1 of 7.
    1  2  3  4  5  6  7  Next»
    EudraCT Number: 2004-000963-81 Sponsor Protocol Number: PM0259CA221B0 Start Date*: 2004-11-15
    Sponsor Name:Robapharm AG
    Full Title: A Randomised Phase II study of Oral Vinorelbine or I.V. Vinorelbine in patients with metastatic breast cancer previously treated with anthracyclines
    Medical condition: Treatment in metastatic breast cancer previously treated with anthracyclines
    Disease:
    Population Age: Elderly Gender: Female
    Trial protocol: AT (Completed) BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-000661-20 Sponsor Protocol Number: ICO Start Date*: 2019-05-31
    Sponsor Name:Vilnius University Hospital Santaros klinikos
    Full Title: Ivabradine to prevent anthracycline-induced cardiotoxicity: a prospective randomized open label clinical trial.
    Medical condition: Cancers treated with anthracyclines: leukemias, limphomas, breast, stomach, uterine, ovarian, lung.
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: LT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-005213-39 Sponsor Protocol Number: CJP4.2 Start Date*: 2013-04-10
    Sponsor Name:CENTRE JEAN PERRIN
    Full Title: Phase II pilot study assessing efficacy of a Cisplatine – Métronomic Cyclophosphamide treatment in Patients with Stade IV Triple Negative breast Cancer Secondary Resistant to Anthracyclines and T...
    Medical condition: Triple negative metastatic breast cancer resistant secondary to anthracyclines and taxanes
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-004618-24 Sponsor Protocol Number: 012018CONTROL Start Date*: 2018-08-03
    Sponsor Name:IRCCS ISTITUTO CLINICO HUMANITAS
    Full Title: Evaluation of CardioprOtection by the use of betablocker Nebivolol in paTients with bReast cancer Or diffuse Large B cell lymphoma undergoing chemotherapy with anthracyclines: a randomized controll...
    Medical condition: To prevent cardiotoxicity of chemotherapeutic agents (anthracyclines)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10042613 - Surgical and medical procedures 10008444 Chemotherapy cardiotoxicity attenuation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-000665-35 Sponsor Protocol Number: PM0259CA220B0 Start Date*: 2004-09-08
    Sponsor Name:Pierre Fabre Medicament
    Full Title: Phase II study of oral vinorelbine in combination with capecitabine in metastatic breast cancer patients previously treated with anthracyclines and taxanes
    Medical condition: Treatment in metastatic breast cancer women previously treated with anthracyclines and taxanes
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2011-002207-15 Sponsor Protocol Number: Cardiorete Start Date*: 2011-12-27
    Sponsor Name:FONDAZIONE DEL PIEMONTE PER L'ONCOLOGIA IRCC DI CANDIOLO
    Full Title: A prospective study with beta-blockers and ACE-inhibitors in patients operable breast cancer experiencing mild cardiac toxicity during treatment with anthracycline and/or trastuzumab
    Medical condition: patients experiencing mild cardiotoxicity during treatment with anthracycline and/or trastuzumab for operable breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-006259-12 Sponsor Protocol Number: 1814 Start Date*: 2012-09-03
    Sponsor Name:Jules Bordet Institute
    Full Title: Phase II study on prospective evaluating the quantification of total choline by magnetic resonance spectroscopy (MRS) in breast tumours as an early predictive marker of neoadjuvant chemotherapy res...
    Medical condition: Early breast cancer requiring neoadjuvant chimiotherapy
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006190 Breast cancer invasive NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-000220-14 Sponsor Protocol Number: TT 04 Start Date*: 2006-03-23
    Sponsor Name:TopoTarget A/S
    Full Title: A therapeutic and pharmacokinetic study of Savene (dexrazoxane) in the treatment of accidental anthracycline extravasation
    Medical condition: Accidental extravasation of anthracyclines
    Disease: Version SOC Term Classification Code Term Level
    7.1 10022062 pref
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-005164-83 Sponsor Protocol Number: BR2056 Start Date*: 2006-06-15
    Sponsor Name:Southampton University Hospitals NHS Trust [...]
    1. Southampton University Hospitals NHS Trust
    2. University of Southampton
    Full Title: A PHASE 2 STUDY OF CARBOPLATIN IN COMBINATION WITH GEMCITABINE AS A DOSE DENSE SCHEDULE IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER THAT ARE RESISTANT TO ANTHRACYCLINES & TAXANES.
    Medical condition: Metastatic breast cancer
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-004902-82 Sponsor Protocol Number: BO28407 Start Date*: 2014-01-13
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE III TRIAL COMPARING TRASTUZUMAB PLUS PERTUZUMAB PLUS A TAXANE FOLLOWING ANTHRACYCLINES VERSUS TRASTUZUMAB EMTANSINE PLUS PERTUZUMAB FOLLOWING ANTHRACYCL...
    Medical condition: HER2-positive operable primary breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER-2 positive breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) GB (GB - no longer in EU/EEA) HU (Completed) DE (Completed) CZ (Completed) ES (Temporarily Halted) NO (Completed) BE (Prematurely Ended) SE (Prematurely Ended) PL (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2005-002004-42 Sponsor Protocol Number: OPHA 05-55 Start Date*: 2005-09-23
    Sponsor Name:Grupo Oncopaz y Hospitales Asociados
    Full Title: "Phase IV-II safety protocol, open-label , not randomized, of Myocet® in combination with Taxotere® as first line antineoplasic treatment in patients with advanced breast cancer”Protocolo de trata...
    Medical condition: Advanced Breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-005683-87 Sponsor Protocol Number: VNBCAPTAX Start Date*: 2006-02-22
    Sponsor Name:AZIENDA OSPEDALIERA S. LUIGI GONZAGA
    Full Title: VINORELBINA CAPECITABIME PACLITAXEL AS FIRST LINE THERAPY IN ADVANCED BREAST CANCER PATIENTS PRETREATED WITH ADJUVANT ANTHRACYCLINES
    Medical condition: METASTATIC BREAST CANCER
    Disease: Version SOC Term Classification Code Term Level
    6.1 10055113 PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-003752-38 Sponsor Protocol Number: om 169 Start Date*: 2003-12-09
    Sponsor Name:OSPEDALE ONCOLOGICO DI BARI
    Full Title: A phase II study of Capecitabine in combination with oral vinorelbine in advanced Breast Cancer
    Medical condition: advancer breast carcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006279 Breast neoplasm LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-002248-26 Sponsor Protocol Number: IEOS701/412 Start Date*: 2012-10-16
    Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA
    Full Title: Prevention of anthracycline-induced cardiotoxicity: a multicentre randomizedtrial comparing two therapeutic strategies.
    Medical condition: Anthracycline-­‐induced cardiotoxicity
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10008444 Chemotherapy cardiotoxicity attenuation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-003582-16 Sponsor Protocol Number: dense get 2005 Start Date*: 2006-07-11
    Sponsor Name:AZIENDA OSPEDALIERA POLICLINICO DI MODENA
    Full Title: Dose-dense treatment with gemcitabine, epirubicin and paclitaxel GET combination in advanced breast cancer a phase II parallel study
    Medical condition: Women with advanced metastatic breast cancer, not previously treated with anthracyclines or taxanes
    Disease: Version SOC Term Classification Code Term Level
    6.1 10006292 HLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2004-000618-38 Sponsor Protocol Number: XRP9881B-3001 Start Date*: 2005-10-24
    Sponsor Name:Aventis Pharmaceuticals Inc.
    Full Title: A randomized, open-label, phase III study of RPR109881 IV every 3 weeks versus capecitabine (Xeloda®) tablets twice daily for 2 weeks in 3-week cycles in patients with metastatic breast cancer prog...
    Medical condition: Metastatic breast cancer patients progressing after taxanes and anthracyclines therapy.
    Disease: Version SOC Term Classification Code Term Level
    10055113
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-003459-31 Sponsor Protocol Number: 2016/816 Start Date*: 2016-10-10
    Sponsor Name:Helse Bergen, Haukeland University Hospital
    Full Title: Treatment of patients with advanced breast cancer harboring TP53 mutations with dose-dense cyclophosphamide - the p53 trial
    Medical condition: Locally advanced breast cancer and metastatic breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2004-000572-14 Sponsor Protocol Number: EFC6088 (XRP9881B/2001) Start Date*: 2004-10-08
    Sponsor Name:Aventis Pharmaceuticals, Inc. (a subsidiary of sanofi-aventis group)
    Full Title: Phase II multicenter, open label, non-randomized study of intravenous RPR109881 q 3 weeks in patients with metastatic breast cancer progressing after therapy with anthracyclines, taxanes, and capec...
    Medical condition: Metastatic breast cancer patients after failure to anthracyclines, taxanes and capecitabine.
    Disease: Version SOC Term Classification Code Term Level
    10055113
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) IT (Completed) ES (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2009-010290-21 Sponsor Protocol Number: UMCNONCO200902 Start Date*: 2009-05-20
    Sponsor Name:University Medical Centre Nijmegen St Radboud
    Full Title: A phase Ib study of combination of temsirolimus (Torisel®) and pegylated liposomal doxorubicin (PLD, Doxil®/ Caelyx®) in advanced or recurrent breast, endometrial and ovarian cancer
    Medical condition: advanced or therapy refractory breast cancer, endometrial cancer, or ovarian cancer.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-002103-32 Sponsor Protocol Number: 50-03B Start Date*: 2005-03-02
    Sponsor Name:GELA-Recherche Clinique
    Full Title: Phase III multicentre open-label randomised study of ICE plus Rituximab (R-ICE) versus DHAP plus Rituximab (R-DHAP) in previously treated patients with CD 20 positive diffuse large B-cell lymphoma,...
    Medical condition: CD 20 positive diffuse large B cell lymphoma
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 19 18:38:04 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA